Mutations in the polycomb-associated protein ASXL1 are present across the myeloid neoplasms and ubiquitously associated with adverse clinical outcome in every subtype of myeloid leukemia7, 8, 49, 50, 51. Here, ASXL1 is linked to myeloid neoplasm.